Aa
NATAP/EASL: HBV Relapse Predictors When Stopping NUC Therapy
Another study reported by Natap. Do read the full report.
LOW HBV DNA AND HBSAG LEVELS AT 24 WEEKS OFF-TREATMENT PREDICT SUSTAINED RESPONSE AND HBSAG LOSS IN PATIENTS WHO DISCONTINUED ANTIVIRAL THERAPY.
CONCLUSION
Serum levels of HBV DNA and HBsAg at FU W24 can be used to predict subsequent clinical relapse and HBsAg clearance in patients who discontinued NUC therapy
M. J. Sonneveld1*, S.-M. Chiu2*, J.Y. Park3, S.M. Brakenhoff1, A. Kaewdech4, W.K. Seto5, Y. Tanaka6, I. Carey7, M. Papatheodoridi8, P. Colombatto9, F. van Bömmel10, T. Berg10, F. Zoulim11, S.H. Ahn3, G.N. Dalekos12, N.S. Erler13,14, M. Brunetto9, H. Wedemeyer15, M. Cornberg15, M.F. Yuen5, K. Agarwal7, A. Boonstra1, M. Buti16, T. Piratvisuth4, G. Papatheodoridis8, and C.-H. Chen2* and B. Maasoumy15* for the CREATE study group
Departments of 1Gastroenterology and Hepatology, Erasmus MC University Medical Center, Rotterdam, The Netherlands; 2Internal Medicine, Koahsiung Chang Gung Memorial Hospital, Kaohsiung, Taiwan; 3Internal Medicine, Yonsei University College of Medicine, Seoul, Korea; 4Faculty of Medicine, Prince of Songkla University, Hatyai, Thailand; 5Department of Medicine, State Key Laboratory for Liver Research, The University of Hong Kong, Hong Kong; 6Department of Gastroenterology & Hepatology, Kumamoto University, Kumamoto, Japan; 7Institute of Liver Studies, King’s College Hospital, London, United Kingdom; 8Department of Gastroenterology, “Laiko” General Hospital of Athens, National and Kapodistrian University of Athens, Greece; 9Hepatology Unit, University Hospital of Pisa, Pisa, Italy; 10Division of Hepatology, Clinic for Oncology, Gastroenterology, Hepatology, Infectious Diseases and Pneumology, University Clinic Leipzig, Germany; 11INSERM Unit 1052, Lyon, France; 12Medicine and Research Laboratory of Internal Medicine, National Expertise Center of Greece in Autoimmune Liver Diseases, Full Member of the European Reference Network on Hepatological Diseases, General University Hospital of Larissa, Larissa, Greece; 13Department of Biostatistics, Erasmus MC University Medical Center, Rotterdam, The Netherlands; 14Department of Epidemiology, Erasmus MC University Medical Center, Rotterdam, The Netherlands; 15Department of Gastroenterology and Hepatology, Hannover Medical School, Hannover, Germany; 16Liver Unit, Department of Internal Medicine, Hospital Universitari Vall d’Hebron and Ciberehd del Intituto Carlos III de Barcelona, Spain. *shared first and senior authorships.
LOW HBV DNA AND HBSAG LEVELS AT 24 WEEKS OFF-TREATMENT PREDICT SUSTAINED RESPONSE AND HBSAG LOSS IN PATIENTS WHO DISCONTINUED ANTIVIRAL THERAPY.
CONCLUSION
Serum levels of HBV DNA and HBsAg at FU W24 can be used to predict subsequent clinical relapse and HBsAg clearance in patients who discontinued NUC therapy
M. J. Sonneveld1*, S.-M. Chiu2*, J.Y. Park3, S.M. Brakenhoff1, A. Kaewdech4, W.K. Seto5, Y. Tanaka6, I. Carey7, M. Papatheodoridi8, P. Colombatto9, F. van Bömmel10, T. Berg10, F. Zoulim11, S.H. Ahn3, G.N. Dalekos12, N.S. Erler13,14, M. Brunetto9, H. Wedemeyer15, M. Cornberg15, M.F. Yuen5, K. Agarwal7, A. Boonstra1, M. Buti16, T. Piratvisuth4, G. Papatheodoridis8, and C.-H. Chen2* and B. Maasoumy15* for the CREATE study group
Departments of 1Gastroenterology and Hepatology, Erasmus MC University Medical Center, Rotterdam, The Netherlands; 2Internal Medicine, Koahsiung Chang Gung Memorial Hospital, Kaohsiung, Taiwan; 3Internal Medicine, Yonsei University College of Medicine, Seoul, Korea; 4Faculty of Medicine, Prince of Songkla University, Hatyai, Thailand; 5Department of Medicine, State Key Laboratory for Liver Research, The University of Hong Kong, Hong Kong; 6Department of Gastroenterology & Hepatology, Kumamoto University, Kumamoto, Japan; 7Institute of Liver Studies, King’s College Hospital, London, United Kingdom; 8Department of Gastroenterology, “Laiko” General Hospital of Athens, National and Kapodistrian University of Athens, Greece; 9Hepatology Unit, University Hospital of Pisa, Pisa, Italy; 10Division of Hepatology, Clinic for Oncology, Gastroenterology, Hepatology, Infectious Diseases and Pneumology, University Clinic Leipzig, Germany; 11INSERM Unit 1052, Lyon, France; 12Medicine and Research Laboratory of Internal Medicine, National Expertise Center of Greece in Autoimmune Liver Diseases, Full Member of the European Reference Network on Hepatological Diseases, General University Hospital of Larissa, Larissa, Greece; 13Department of Biostatistics, Erasmus MC University Medical Center, Rotterdam, The Netherlands; 14Department of Epidemiology, Erasmus MC University Medical Center, Rotterdam, The Netherlands; 15Department of Gastroenterology and Hepatology, Hannover Medical School, Hannover, Germany; 16Liver Unit, Department of Internal Medicine, Hospital Universitari Vall d’Hebron and Ciberehd del Intituto Carlos III de Barcelona, Spain. *shared first and senior authorships.
Have an Answer?
You are reading content posted in the Hepatitis B Community
A list of national and international resources and hotlines to help connect you to needed health and medical services.
Herpes sores blister, then burst, scab and heal.
Herpes spreads by oral, vaginal and anal sex.
STIs are the most common cause of genital sores.
Condoms are the most effective way to prevent HIV and STDs.
PrEP is used by people with high risk to prevent HIV infection.
